Zobrazeno 1 - 10
of 228
pro vyhledávání: '"Donald L, Lamm"'
Autor:
Noah M. Hahn, Michael A. O'Donnell, Jason A. Efstathiou, Marianna Zahurak, Gary L. Rosner, Jeff Smith, Max R. Kates, Trinity J. Bivalacqua, Phuoc T. Tran, Daniel Y. Song, Alex S. Baras, Andres Matoso, Woonyoung Choi, Kellie N. Smith, Drew M. Pardoll, Luigi Marchionni, Bridget McGuire, Mary Grace Phelan, Burles A. Johnson, Tanya O'Neal, David J. McConkey, Tracy L. Rose, Marc Bjurlin, Emerson A. Lim, Charles G. Drake, James M. McKiernan, Israel Deutsch, Christopher B. Anderson, Donald L. Lamm, Daniel M. Geynisman, Elizabeth R. Plimack, Mark A. Hallman, Eric M. Horwitz, Essel Al-Saleem, David Y.T. Chen, Richard E. Greenberg, Alexander Kutikov, Gordon Guo, Timothy A. Masterson, Nabil Adra, Hristos Z. Kaimakliotis
Publikováno v:
European Urology. 83:486-494
Autor:
Max, Kates, Ahmed M, Mansour, Donald L, Lamm, Neal, Shore, Holly, Maulhardt, Alison, Wendt, James, Verco, Alyson, Marin, Karan, Dewnani, Shelagh, Verco, Gere S, diZerega
Publikováno v:
Journal of Urology. 208:821-829
We investigated the safety, preliminary efficacy, and immune effects of large surface area microparticle docetaxel (LSAM-DTX) administered by direct injection after transurethral resection of bladder tumor (TURBT), and by intravesical instillation in
Autor:
Ashish M. Kamat, Joaquim Bellmunt, Matthew D. Galsky, Badrinath R. Konety, Donald L. Lamm, David Langham, Cheryl T. Lee, Matthew I. Milowsky, Michael A. O’Donnell, Peter H. O’Donnell, Daniel P. Petrylak, Padmanee Sharma, Eila C. Skinner, Guru Sonpavde, John A. Taylor, Prasanth Abraham, Jonathan E. Rosenberg
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-16 (2017)
Abstract The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has dem
Externí odkaz:
https://doaj.org/article/a0d0c0551989418f9c28cf0b509924fb
Autor:
Ashish M. Kamat, Niyati Lobo, Seth P. Lerner, Roger Li, Justin T. Matulay, Joan Palou, J. Alfred Witjes, Morgan Rouprêt, Angela B. Smith, Sam S. Chang, Neal D. Shore, Gary D. Steinberg, Colin P. Dinney, Robert S. Svatek, Donald L. Lamm
Publikováno v:
Bladder Cancer
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Bladder Cancer, 8, 113-117
Bladder Cancer, 8, 2, pp. 113-117
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Bladder Cancer, 8, 113-117
Bladder Cancer, 8, 2, pp. 113-117
When it comes to the treatment of patients with non-muscle-invasive bladder cancer (NMIBC) with intravesical bacillus Calmette-Guérin (BCG), two questions must be considered: 1) what dose to give, and 2) for how long? The issue of optimal dose and d
Autor:
Donald L. Lamm, Alvaro Morales
Publikováno v:
Vaccine. 39:7308-7318
BCG remains the most important vaccine for tuberculosis 100 years after its first use, and over the past 4 decades it has become the most widely accepted, effective drug used in the treatment of aggressive localized bladder cancer. This review chroni
Autor:
Lewis J. Thomas, Ryan L. Steinberg, Vignesh T. Packiam, Ian M. McElree, Nathan Brooks, Andrew Vitale, Eric Hyndman, Trafford Crump, Mounica Y. Rao, Donald L. Lamm, Marcus J. Daniels, Max Kates, Supriya Nagaraju, Ashish M. Kamat, Trinity J. Bivalacqua, Sarah L. Mott, Kenneth G. Nepple, Michael A. O'Donnell
Publikováno v:
Clinical Genitourinary Cancer.
Autor:
Girish S. Kulkarni, Kyle A Richards, Peter C. Black, Ricardo A. Rendon, Joseph Chin, Neal D. Shore, Gautam Jayram, Eugene V. Kramolowsky, Daniel Saltzstein, Piyush K. Agarwal, Laurence Belkoff, Michael A. O'Donnell, Ashish M. Kamat, Michael A.S. Jewett, Donald L. Lamm, Victor DeGruttola, Arkady Mandel, Roger Dumoulin-White, Wassim Kassouf
Publikováno v:
Journal of Clinical Oncology. 41:528-528
528 Background: Novel therapies are required for BCG-unresponsive, high risk non-muscle invasive bladder cancer. We report the interim results of a Phase II Clinical Study of Intravesical Photo Dynamic Therapy (PDT) in patients with BCG-Unresponsive
Autor:
Jonathan Wang, William C. DeWolf, M. Eric Hyndman, Trafford Crump, Marcus J. Daniels, Ryan L. Steinberg, Donald L. Lamm, Ashish M. Kamat, Max Kates, Mounica Y. Rao, Kenneth G. Nepple, Nathan A. Brooks, Andrew Vitale, Michael A. O’Donnell, Sarah L. Mott, Trinity J. Bivalacqua, Lewis Thomas, Supriya Nagaraju
Publikováno v:
Journal of Urology. 203:902-909
Rescue intravesical therapies for patients with bacillus Calmette-Guérin failure nonmuscle invasive bladder cancer remain a critical focus of ongoing research. Sequential intravesical gemcitabine and docetaxel therapy has shown safety and efficacy i
Publikováno v:
Bladder Cancer. 6:25-32
BACKGROUND: Bacillus Calmette-Guerin (BCG) is the recommended therapy for high and intermediate risk non-muscle invasive bladder cancer (NMIBC), but treatment failure is common. While a radical cystectomy is recommended after BCG failure, some patien
Autor:
Roger Buckley, Mark S. Soloway, Raj Persad, J. Alfred Witjes, Maurizio Brausi, Marc Colombel, Donald L. Lamm, Ashish M. Kamat, Andreas Boehle, Justin T. Matulay, Joan Palou
Publikováno v:
BJU International, 125, 4, pp. 497-505
BJU International, 125, 497-505
BJU International, 125, 497-505
Contains fulltext : 220546.pdf (Publisher’s version ) (Closed access) OBJECTIVE: To provide a contemporary update and recommendations for the diagnosis and management of low-grade non-muscle-invasive bladder cancer (BCa) based on current literature